Expert Perspectives on Navigating Biomarker Testing for NSCLC Patients

EP: 1.Brief Overview & Key Insights: Current Treatment Practices for ALK+ NSCLC

Now Viewing

EP: 2.Expert Perspectives on Navigating Biomarker Testing for NSCLC Patients

EP: 3.From Results to Therapy: Preparing Patients for ALK Inhibitor Therapy

EP: 4.Key Considerations for First-Line ALK Inhibitor Treatment Selection

EP: 5.Clinical Perspectives on Managing ALK Inhibitor Adverse Events

EP: 6.Patient Case – Treatment Considerations for ALK+ NSCLC

EP: 7.Monitoring Strategies for ALK Inhibitor Therapy

EP: 8.Patient Education for Long-Term Success on ALK Inhibitor Therapy

EP: 9.Treatment Transitions in ALK+ NSCLC

EP: 10.Long-Term Care in ALK+ NSCLC

EP: 11.Practice Pearls & Resources for ALK+ NSCLC

This segment focuses on the critical role nurses and advanced practice providers play in coordinating comprehensive biomarker testing for newly diagnosed patients with non–small cell lung cancer (NSCLC). Early and complete molecular profiling, including ALK testing, is essential for determining the most appropriate therapy. The panel shares best practices for embedding this into the clinical workflow.

Communication and coordination with multidisciplinary teams—including pathology, lab services, and oncology—are vital to ensuring test results are received quickly and comprehensively. The panelists describe systems that support this, including reflex testing protocols and pre-authorization strategies, which help to minimize delays in treatment.

Equally important is the emotional support offered to patients and families during this waiting period. Clinicians work to educate patients about why it is critical to wait for molecular results before starting therapy. Through ongoing dialogue, reassurance, and education, providers help patients remain informed and engaged in the decision-making process.